Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + Irinotecan Liposome +/- Famitinib in ES-SCLC
NCT06332950Phase 2Not yet recruiting
- Start
- Apr 2024
- Primary completion
- Apr 2027
- Modality
- Immune Checkpoint Inhibitors, Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab, famitinib, irinotecan liposome injection in small cell lung cancer (SCLC). Planned start Apr 2024; status: not yet recruiting.
02
Drugs
adebrelimabfamitinibirinotecan liposome injection
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06332950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06332950.